PAUL J. MARTIN, M.D.; HOWARD M. SHULMAN, M.D.; WILLIAM H. SCHUBACH, M.D.; JOHN A. HANSEN, M.D.; ALEXANDER FEFER, M.D.; GEORGE MILLER, M.D.; E. DONNALL THOMAS, M.D.
Two patients with acute leukemia were treated with chemoradiotherapy and allogeneic bone marrow transplantation. Despite the prophylactic use of methotrexate after grafting, both patients developed severe graft-versus-host disease that was refractory to treatment with methylprednisolone. The graft-versus-host disease was then treated with a monoclonal antibody, 64.1, that reacts with a p19 antigen on human T cells. The disease responded dramatically to this treatment, but both patients subsequently developed a fatal polyclonal lymphoproliferative disorder arising in donor-derived B cells. Hybridization studies showed Epstein-Barr virus in both tumors. The combined effect of severe end-stage graft-versus-host disease and potent immunosuppressive therapy probably resulted in a progressive immunodeficiency syndrome that abrogated the T-cell-mediated surveillance mechanism that normally modulates the proliferation of Epstein-Barr-virus-infected B lymphocytes.
Learn more about subscription options.
Register Now for a free account.
MARTIN PJ, SHULMAN HM, SCHUBACH WH, HANSEN JA, FEFER A, MILLER G, et al. Fatal Epstein-Barr-Virus-Associated Proliferation of Donor B Cells After Treatment of Acute Graft-Versus-Host Disease with a Murine Anti-T-Cell Antibody. Ann Intern Med. 1984;101:310–315. doi: 10.7326/0003-4819-101-3-310
Download citation file:
Published: Ann Intern Med. 1984;101(3):310-315.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only